HER2DX Assay and Survival Outcomes in HER2-Positive Breast Cancer

A recent meta-analysis by Villacampa et al published in The Lancet Oncology highlights the prognostic significance of the HER2DX assay risk score for event-free survival in patients with early-stage, HER2-positive breast cancer. Analyzing data from 11 studies with over 2,500 patients, the results indicated that the HER2DX score is predictive of outcomes, demonstrating a marked difference in event-free survival rates between low- and high-risk groups. Findings support the integration of HER2DX in treatment decision-making processes to enhance patient outcomes.